Alfuzosin is an alpha-adrenergic antagonist indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

The CYP3A4 liver enzyme metabolizes alfuzosin. Genetic variations in CYP3A4 and the use of medications inhibiting this enzyme may affect alfuzosin blood concentrations and the risk of side effects.

Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates. Use with caution in patients with severe renal impairment (creatinine clearance <30 mL/min) and in patients with mild hepatic impairment. Alfuzosin should not be used in combination with other alpha-adrenergic antagonists. Prostate carcinoma should be ruled out before treatment. Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery may require modifications to the surgical technique. Discontinue alfuzosin if symptoms of angina pectoris appear or worsen. Use caution in patients with a history of QT prolongation or taking medications that prolong the QT interval.

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021287s018lbl.pdf